T D Nelin1, E Pena2,3, T Giacomazzi2, S Lee2, J W Logan2,3, M Moallem2,3, R Bapat2,3, E G Shepherd2,3, L D Nelin1,2,3. 1. Center for Perinatal Research, Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. 2. Small Baby ICU, Nationwide Children's Hospital, Columbus, OH, USA. 3. Department of Pediatrics, The Ohio State University, Columbus, OH, USA.
Abstract
OBJECTIVE: We examined data from a contemporary cohort of extreme prematurity (EP) infants admitted to an all-referral Children's Hospital neonatal intensive care unit (NICU) to determine whether prophylactic indomethacin (PI) may continue to benefit these patients. STUDY DESIGN: An observational study utilizing the small baby ICU data registry that was queried for all EP infants admitted between 2005 and 2014 with documentation of PI use (671 total EP infants; 141 (21%) did not receive PI (control); 530 (79%) received PI (PI). This cohort of EP infants was born at outside hospitals and transferred to our level IV NICU with a mean age on admission of 13 days, well after the PI would have been administered. RESULTS: No difference existed between the control and PI groups in gestational age, birth weight, severity of illness, other in-hospital outcomes or developmental delay. PI infants had a significantly lower mortality rate (P=0.0004), lower relative risk (RR) for mortality 0.52 (95% confidence interval (CI) 0.37 to 0.73, P=0.0001) and lower RR of developing the combined outcome of death or bronchopulmonary dysplasia (RR 0.91, 95% CI 0.85 to 0.98, P=0.012) when compared with the control group. Notably, there was no significant effect of PI on incidence of severe intraventricular hemorrhage or patent ductus arteriosus ligation. CONCLUSION: PI administration was associated with improved survival in EP infants referred to a level IV Children's Hospital NICU.
OBJECTIVE: We examined data from a contemporary cohort of extreme prematurity (EP) infants admitted to an all-referral Children's Hospital neonatal intensive care unit (NICU) to determine whether prophylactic indomethacin (PI) may continue to benefit these patients. STUDY DESIGN: An observational study utilizing the small baby ICU data registry that was queried for all EP infants admitted between 2005 and 2014 with documentation of PI use (671 total EP infants; 141 (21%) did not receive PI (control); 530 (79%) received PI (PI). This cohort of EP infants was born at outside hospitals and transferred to our level IV NICU with a mean age on admission of 13 days, well after the PI would have been administered. RESULTS: No difference existed between the control and PI groups in gestational age, birth weight, severity of illness, other in-hospital outcomes or developmental delay. PI infants had a significantly lower mortality rate (P=0.0004), lower relative risk (RR) for mortality 0.52 (95% confidence interval (CI) 0.37 to 0.73, P=0.0001) and lower RR of developing the combined outcome of death or bronchopulmonary dysplasia (RR 0.91, 95% CI 0.85 to 0.98, P=0.012) when compared with the control group. Notably, there was no significant effect of PI on incidence of severe intraventricular hemorrhage or patent ductus arteriosus ligation. CONCLUSION: PI administration was associated with improved survival in EP infants referred to a level IV Children's Hospital NICU.
Authors: B Schmidt; P Davis; D Moddemann; A Ohlsson; R S Roberts; S Saigal; A Solimano; M Vincer; L L Wright Journal: N Engl J Med Date: 2001-06-28 Impact factor: 91.245
Authors: Ursula Guillén; Sara DeMauro; Li Ma; John Zupancic; Robin Roberts; Barbara Schmidt; Haresh Kirpalani Journal: Arch Pediatr Adolesc Med Date: 2012-02
Authors: Barbara Schmidt; Robin S Roberts; Peter Davis; Lex W Doyle; Keith J Barrington; Arne Ohlsson; Alfonso Solimano; Win Tin Journal: N Engl J Med Date: 2007-11-08 Impact factor: 91.245
Authors: Hibo H Abdi; Carl H Backes; Molly K Ball; Maria M Talavera-Barber; Mark A Klebanoff; Sudarshan R Jadcherla; Tahagod H Mohamed; Jonathan L Slaughter Journal: J Perinatol Date: 2021-03-04 Impact factor: 2.521
Authors: Sanjay Chawla; Girija Natarajan; Abbot R Laptook; Dhuly Chowdhury; Edward F Bell; Namasivayam Ambalavanan; Waldemar A Carlo; Marie Gantz; Abhik Das; Jose L Tapia; Heidi M Harmon; Seetha Shankaran Journal: Pediatr Res Date: 2022-03-17 Impact factor: 3.953
Authors: Ijab Khanafer-Larocque; Amuchou Soraisham; Amelie Stritzke; Essa Al Awad; Sumesh Thomas; Prashanth Murthy; Majeeda Kamaluddeen; James N Scott; Khorshid Mohammad Journal: Front Pediatr Date: 2019-10-22 Impact factor: 3.418
Authors: Esther J S Jansen; Tim Hundscheid; Wes Onland; Elisabeth M W Kooi; Peter Andriessen; Willem P de Boode Journal: Front Pediatr Date: 2021-02-09 Impact factor: 3.418